Developing new vaccines to protect against infectious diseases at home and abroad
09 July 2021
11. Other, 1-hour Integrated Symposium
11c. Other
•
2795
•
14:15
>
15:15
•
Developing new vaccines to protect against infectious diseases at home and abroad
•
16. Integrated Sessions – 4
11c. Other
The aim is to share initial results of 2 novel vaccine candidates: a whole virus, inactivated, adjuvanted SARS-CoV-2 vaccine to prevent against COVID-19 at home and a live-attenuated, single dose vaccine for protection against chikungunya disease when travelling abroad. For VLA2001, the results of the first-in-human Phase 1/2 study evaluating three dose levels (low, medium, high) for safety, tolerability and immunogenicity in a two-dose schedule three weeks apart will be presented, plus Phase 3 design and future research priorities. Chikungunya is an emerging viral disease transmitted to humans by infected mosquitos, and cause fever to severe arthralgia. Chikungunya is a public health threat as no vaccine or drug against the virus exist. The results of a dose-escalation study with VLA1553 will be presented. A Phase 3 study in approximately 4,000 healthy adults is initiated, through a program granted as Fast Track by FDA and PRIME by EMA
14:15
•
2795-1
•
The portfolio approach: lessons learned from the UK vaccine task forces response to COVID-19
>
A.
Adam
FINN (Bristol)
14:25
•
2795-2
•
Interactive questions
14:30
•
2795-3
•
Travel and the pandemic: challenges faced by specialist travel clinics and how travel changed
>
T.
Tomas
JELINEK (Berlin)
14:40
•
2795-4
•
Interactive questions
14:45
•
2795-5
•
Leveraging established technologies: an inactivated vaccine candidate (VLA2001) with a novel adjuvant combination to protect against COVID-19
>
A.
Adam
FINN (Bristol)
14:55
•
2795-6
•
Interactive questions
15:00
•
2795-7
•
Emerging Infectious Disease: Chikungunya as a public health threat and introduction to a novel vaccine candidate (VLA1553)
>
T.
Tomas
JELINEK (Berlin)
15:10
•
2795-8
•
Interactive questions
|